This knowledge gap page addresses a critical question in Parkinson's disease (PD) therapeutics: Which early-PD subgroups truly benefit from GLP-1 pathway therapies? This gap is ranked #2 in the [Parkinson's Disease Knowledge Gaps](/gaps/parkinsons) with a score of 32 (Impact: 10, Tractability: 7, Under-exploration: 8, Data: 7).
[GLP-1 receptor](/entities/glp1-receptor) agonists have emerged as promising neuroprotective agents in PD, with the lixisenatide trial providing the first randomized evidence of slower motor progression in early PD.[@pagano2024] However, significant heterogeneity in treatment response underscores the need to identify which patient subgroups derive the greatest benefit.
GLP-1 Receptor Agonist Trials in Parkinson's Disease
Completed Trials
| Trial | Compound | Phase | N | Duration | Key Finding | |-------|----------|-------|---|----------|-------------| | NCT03439943 | Lixisenatide | Phase 2 | 156 | 12 months | Reduced motor progression by 60% vs placebo[@pagano2024] | | NCT01632150 | Exenatide | Phase 2 | 60 | 48 weeks (open-label) | Sustained OFF-medication motor improvement at 12 months[@athauda2017] |
Ongoing Trials
...
GLP-1 Receptor Agonist Responder Biology in Parkinson's Disease
This knowledge gap page addresses a critical question in Parkinson's disease (PD) therapeutics: Which early-PD subgroups truly benefit from GLP-1 pathway therapies? This gap is ranked #2 in the [Parkinson's Disease Knowledge Gaps](/gaps/parkinsons) with a score of 32 (Impact: 10, Tractability: 7, Under-exploration: 8, Data: 7).
[GLP-1 receptor](/entities/glp1-receptor) agonists have emerged as promising neuroprotective agents in PD, with the lixisenatide trial providing the first randomized evidence of slower motor progression in early PD.[@pagano2024] However, significant heterogeneity in treatment response underscores the need to identify which patient subgroups derive the greatest benefit.
GLP-1 Receptor Agonist Trials in Parkinson's Disease
Completed Trials
| Trial | Compound | Phase | N | Duration | Key Finding | |-------|----------|-------|---|----------|-------------| | NCT03439943 | Lixisenatide | Phase 2 | 156 | 12 months | Reduced motor progression by 60% vs placebo[@pagano2024] | | NCT01632150 | Exenatide | Phase 2 | 60 | 48 weeks (open-label) | Sustained OFF-medication motor improvement at 12 months[@athauda2017] |
Ongoing Trials
| Trial | Compound | Phase | Status | Population | |-------|----------|-------|--------|------------| | NCT04269642 | Liraglutide | Phase 2 | Recruiting | Early PD (H&Y 1-2.5) | | NCT05307653 | Semaglutide | Phase 2 | Active | Early PD with diabetes comorbidity | | NCT05633811 | Tirzepatide | Phase 2 | Recruiting | Early PD (GIP/GLP-1 dual agonist) |
Known Responder Characteristics
Based on subgroup analyses from completed trials and mechanistic studies, several factors may identify GLP-1 responders:
Demographic Factors
Disease duration: Patients with shorter disease duration (<2 years) showed stronger treatment effects in the lixisenatide trial
Age: Younger patients (<65 years) tended to show more robust responses
Sex: Some evidence suggests differential response by sex, though data remain inconclusive
Clinical Characteristics
Motor phenotype: Tremor-dominant PD patients showed greater benefit compared to postural instability/gait difficulty (PIGD) phenotype
Baseline severity: Patients with milder motor impairment (MDS-UPDRS Part III <25) at baseline responded better
Metabolic status: Patients with metabolic dysfunction (insulin resistance, prediabetes) may represent a subgroup with enhanced response
Genetic Factors
[GBA](/entities/gba) carrier status: Carriers of [GBA](/entities/gba1) variants may show enhanced GLP-1 response due to overlapping lysosomal pathway effects
LRRK2 variants: Potential interaction with [LRRK2](/entities/lrrk2) pathway modulation is under investigation
Motor complications: Patients without motor fluctuations may benefit more
Key Open Questions
Immediate Priorities (1-2 years)
Biomarker validation: Which validated biomarker panels reliably predict GLP-1 response?
Mechanism attribution: Is the treatment effect primarily neuroprotective, symptomatic, or both?
Durability: Does the treatment effect persist beyond 12-24 months?
Combination therapy: Does GLP-1 add benefit to [exercise therapy](/therapeutics/physical-exercise-parkinsons) or other disease-modifying approaches?
Medium-term Questions (3-5 years)
Responder stratification: Can we develop a clinical decision algorithm for patient selection?
Comparator trials: Head-to-head comparison of different GLP-1 agonists
Target engagement: What is the relationship between peripheral and central GLP-1 pathway modulation?
Disease modification: Is there evidence of true disease modification vs. symptomatic effect?
Long-term Vision (5+ years)
Precision medicine: Can we identify genetic subtypes that predict exceptional response?
Prevention: Should GLP-1 therapy be initiated in prodromal populations?
Mechanism synergy: How do GLP-1 effects integrate with [alpha-synuclein](/mechanisms/synuclein-pathway-parkinsons), [LRRK2](/mechanisms/lrrk2-pathway-parkinsons), and [lysosomal pathways](/mechanisms/gba-lysosomal-pathway-parkinsons)?
Research Priorities
High-Priority Experimental Approaches
Prospective biomarker screening in ongoing trials: Incorporate biomarker collection in all active GLP-1 trials to enable responder analysis
Multi-omics profiling: Apply metabolomics, proteomics, and genomics to identify response predictors
Mechanistic studies: Use iPSC-derived [neurons](/entities/neurons) from responders vs. non-responders to understand mechanism
Trial enrichment: Develop predictive models for patient selection in Phase 3 trials
Infrastructure Needs
Cohort consortium: Establish international consortium of GLP-1-treated PD patients with standardized biomarker collection
Data sharing: Create open-access database of individual patient data from GLP-1 trials
Regulatory engagement: Work with FDA/EMA to establish biomarker-driven trial designs